1,3-Dioleoyl-sn-glycerol-d5

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 甘油脂
• 英文名称: 1,3-Dioleoyl-sn-glycerol-d5
• 英文别名: [1,1,2,3,3-pentadeuterio-2-hydroxy-3-[(Z)-octadec-9-enoyl]oxypropyl] (Z)-octadec-9-enoate
• 化学式: C39H72O5
• 分子量: 626.0
• InChiKey: DRAWQKGUORNASA-XZPPQYRVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  14.3
• 重原子数：
  44
• 可旋转键数：
  36
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.85
• 拓扑面积：
  72.8
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• [EN] TREATMENT OF NEURODEGENERATIVE CONDITIONS<br/>[FR] TRAITEMENT D'ETATS NEURODEGENERATIFS
  申请人：BTG INT LTD

  公开号：WO2005018632A1

  公开（公告）日：2005-03-03

  A method is provided for treating a patient in need of therapy for a neurodegenerative disease comprising administering to that patient a therapeutically effective dose of a lipid glyceride comprising a glycerol moiety and a fatty acid moiety, the fatty acid moiety being selected from the group consisting of Ϝ-linolenic acid, dihomo-Ϝ-linolenic acid and arachidonic acid characterised in that the selected fatty acid moiety is attached to the glycerol moiety at its sn-2 position. Preferably the method is that wherein the lipid is administered for a duration and at a dose sufficient to maintain or elevate TGF-β1 levels in the patient to therapeutic levels.

  提供了一种治疗神经退行性疾病患者的方法，包括向该患者施用含有甘油基团和脂肪酸基团的治疗有效剂量的脂质甘油酯，所述脂肪酸基团选自Ϝ-亚麻酸、二油酸和花生四烯酸组成的群体，其特点在于所选的脂肪酸基团附着在甘油基团的sn-2位置。最好的方法是，脂质被施用的持续时间和剂量足以维持或提高患者体内TGF-β1水平至治疗水平。
• [EN] PHARMAACEUTICAL COMPOSITIONS COMPRISING FATTY ACID ESTERS<br/>[FR] COMPOSITIONS PHARMACEUTIQUES COMPRENANT DES ESTERS D'ACIDES GRAS
  申请人：ALKERMES PHARMA IRELAND LTD

  公开号：WO2013142198A1

  公开（公告）日：2013-09-26

  The present invention relates to an injectable, pharmaceutical composition comprising a C1-6 alkyl ester of a C10-20 fatty acid. In an embodiment, the fatty acid is ethyl oleate, isopropyl oleate, ethyl myristate, or isopropyl myristate. These compositions are useful for the delivery of anti-psychotic drugs.

  本发明涉及一种可注射的药物组合物，包括C10-20脂肪酸的C1-6烷基酯。在一种实施例中，脂肪酸为油酸乙酯、油酸异丙酯、肉豆蔻酸乙酯或肉豆蔻酸异丙酯。这些组合物适用于抗精神病药物的输送。
• [EN] PHARMACEUTICAL COMPOSITIONS COMPRISING BENZYL ALCOHOL<br/>[FR] COMPOSITIONS PHARMACEUTIQUES COMPRENANT DE L'ALCOOL BENZYLIQUE
  申请人：ALKERMES PHARMA IRELAND LTD

  公开号：WO2013142205A1

  公开（公告）日：2013-09-26

  The present invention relates to a pharmaceutical composition comprising benzyl alcohol and polyoxyethylene derivatives of sorbitan esters of carboxylic acids that are useful for the delivery of anti-psychotic drugs.

  本发明涉及一种药物组合物，包括苯甲醇和羧酸山梨醇酯的聚氧乙烯衍生物，用于输送抗精神病药物。
• Functional associative coatings for nanoparticles
  申请人：Hainfeld James F.

  公开号：US20080089836A1

  公开（公告）日：2008-04-17

  Described herein are nanoparticles that are coated with a bilayer of molecules formed from surface binding molecules and amphiphatic molecules. The bilayer coating self assembles on the nanoparticles from readily available materials/molecules. The modular design of the bilayer coated nanoparticles provides a means for readily and efficiently optimizing the properties of the bilayer coated nanoparticle compositions. Also described herein are uses of such nanoparticles in medicine, laboratory techniques, industrial and commerical applications.

  本文描述了一种纳米颗粒，其表面涂覆有由表面结合分子和两亲分子形成的双层分子层。该双层涂层可以自组装在纳米颗粒上，使用易得的材料/分子。双层涂层纳米颗粒的模块化设计提供了一种方便和高效地优化其性质的方法。此外，本文还描述了这种纳米颗粒在医学、实验室技术、工业和商业应用中的用途。
• METHODS AND COMPOSITIONS FOR TREATING EDEMA REFRACTORY TO ORAL DIURETICS
  申请人：RESQ Pharmaceuticals LLC

  公开号：US20210169833A1

  公开（公告）日：2021-06-10

  The present invention features methods and compositions for the intranasal, sublingual, and subcutaneous administration of bumetanide for the treatment of subjects suffering from edema refractory to oral diuretics.

  本发明涉及一种治疗口服利尿剂难以治疗的水肿患者的方法和组合物，其特点在于通过鼻内、舌下和皮下途径给予布美他尼德。